Neuronostatin-13 human

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Neuronostatin-13 (Human) is a 13 amino acid residue peptide with carboxyl-terminal amidation, the primary structure is conserved in human chimpanzee and some other mammals.

Neuronostatin-13 (Human) is a 13 amino acid residue peptide with carboxyl-terminal amidation, the primary structure is conserved in human chimpanzee and some other mammals.(In Vitro):Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function. Treatment with Neuronostatin-13 human (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human leads to an increase in phosphorylated PKA at 30 and 40 min.(In Vivo):Infusion with Neuronostatin-13 human delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human challenge. In addition, Neuronostatin-13 human treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human treatment.

——

Others

Other Targets

——

——

——

1096485-24-3

1415.7

C64H110N20O16

>98% (HPLC)

——

——

Sequence:Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2

(-20℃)

With Ice Pack

≥ 2 years